Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionCandriam Luxembourg S.C.A.
Latest Disclosed Ownership275,064 shares
Latest Disclosed Value $ 36,236,931
Candriam Luxembourg S.C.A. reports 6.15% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On April 30, 2026 - Candriam Luxembourg S.C.A. filed a 13F-HR form disclosing ownership of 275,064 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $36,236,931 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on April 30, 2026 disclosing 293,096 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -6.15% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 275,064 -18,032 -6.15 36,237 -12.83 0.1882
2026-04-30 2025-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 293,096 5,451 1.90 41,572 2.95 0.2073
2026-02-13 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 293,096 5,451 41,572 0.2070
2025-11-06 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 287,645 -10,906 -3.65 40,380 7.60 0.2114
2025-08-08 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 298,551 -32,289 -9.76 37,526 2.56 0.2164
2025-05-14 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 330,840 26,868 8.84 36,591 -11.81 0.2292
2025-02-07 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 303,972 -179,269 -37.10 41,492 -25.48 0.2389
2024-11-13 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 483,241 17,774 3.82 55,677 -13.11 0.3199
2024-08-05 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 465,467 149,783 47.45 64,078 47.17 0.3884
2024-05-06 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 315,684 -54,215 -14.66 43,539 -10.67 0.2784
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 369,899 -7,339 -1.95 48,740 14.85 0.3364
2023-11-13 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 377,238 -63,178 -14.35 42,439 2.19 0.3008
2023-08-08 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 440,416 23,236 5.57 41,531 6.86 0.3001
2023-05-12 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 417,180 148,008 54.99 38,867 20.90 0.2696
2023-02-13 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 269,172 -2,309 -0.85 32,148 11.49 0.2169
2022-11-10 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 271,481 -59,448 -17.96 28,835 -10.61 0.2031
2022-08-03 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 330,929 30,722 10.23 32,257 14.62 0.2656
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 300,207 -9,706 -3.13 28,143 6.62 0.1915
2022-02-10 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 309,913 228,400 280.20 26,395 237.62 0.1685
2021-11-09 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 81,513 20 0.02 7,818 -1.42 0.0531
2021-07-20 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 81,493 -80,376 -49.65 7,931 -50.26 0.0543
2021-04-29 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 161,869 0 0.00 15,945 -3.95 0.1327
2021-01-22 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 161,869 5,587 3.57 16,601 10.47 0.1314
2020-10-19 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 156,282 0 0.00 15,027 -21.19 0.1412
2020-07-23 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 156,282 -30,484 -16.32 19,067 -2.84 0.2013
2020-05-26 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 186,766 0 0.00 19,625 -2.24 0.2175
2020-02-05 2019-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 186,766 -17,903 -8.75 20,075 8.85 0.2152
2020-01-21 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 186,766 -17,903 20 214,500.2145
2020-02-05 2019-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 204,669 -63,000 -23.54 18,443 -18.03 0.2444
2019-10-21 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 204,669 -63,000 18 226,215.9105
2019-08-01 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 267,669 -25,000 -8.54 22,500 -12.74 0.2806
2019-05-02 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 292,669 64,600 28.32 25,785 58.33 0.3299
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 228,069 78,000 51.98 16,286 -11.73 0.2503
2018-11-07 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 150,069 69,969 87.35 18,451 134.48 0.2453
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 80,100 15,100 23.23 7,869 45.97 0.1245
2018-05-09 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 65,000 -35,000 -35.00 5,391 -30.52 0.0919
2018-02-07 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,000 -292,000 -74.49 7,759 -67.70 0.1342
2017-11-03 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 392,000 -69,000 -14.97 24,022 13.27 0.4197
2017-07-31 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 461,000 214,000 86.64 21,207 98.27 0.3985
2017-04-21 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 247,000 78,000 46.15 10,696 63.55 0.2071
2017-02-01 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 169,000 46,000 37.40 6,540 4.99 0.1501
2016-11-15 2016-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 123,000 6,700 5.76 6,229 17.84 0.1498
2016-07-26 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 116,300 -2,700 -2.27 5,286 12.92 0.1374
2016-04-27 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 119,000 7,000 6.25 4,681 -26.12 0.1171
2016-01-25 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 112,000 21,000 23.08 6,336 74.98 0.1695
2015-10-19 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 91,000 -14,000 -13.33 3,621 -27.80 0.0889
2015-07-29 2015-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 105,000 -50,000 -32.26 5,015 -18.53 0.1044
2015-05-28 2015-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 155,000 -55,000 -26.19 6,156 31.23 0.1240
2015-04-27 2015-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 155,000 6,155
2015-05-28 2014-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 210,000 210,000 4,691 0.0981
2015-03-26 2014-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 210,000 210,000 4,691 0.0949
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.